Cargando…
An allosteric inhibitor of Mycobacterium tuberculosis ArgJ: Implications to a novel combinatorial therapy
The existing treatment regime against tuberculosis is not adequate, and novel therapeutic interventions are required to target Mycobacterium tuberculosis (Mtb) pathogenesis. We report Pranlukast (PRK) as a novel allosteric inhibitor of Mtb's arginine biosynthetic enzyme, Ornithine acetyltransfe...
Autores principales: | Mishra, Archita, Mamidi, Ashalatha S, Rajmani, Raju S, Ray, Ananya, Roy, Rajanya, Surolia, Avadhesha |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887547/ https://www.ncbi.nlm.nih.gov/pubmed/29483133 http://dx.doi.org/10.15252/emmm.201708038 |
Ejemplares similares
-
Mixed mechanism of conformational selection and induced fit as a molecular recognition process in the calreticulin family of proteins
por: Mamidi, Ashalatha Sreshty, et al.
Publicado: (2022) -
Multivariate PLS Modeling of Apicomplexan FabD-Ligand Interaction Space for Mapping Target-Specific Chemical Space and Pharmacophore Fingerprints
por: Mamidi, Ashalatha Sreshty, et al.
Publicado: (2015) -
Structural Analysis of PfSec62-Autophagy Interacting Motifs (AIM) and PfAtg8 Interactions for Its Implications in RecovER-phagy in Plasmodium falciparum
por: Mamidi, Ashalatha Sreshty, et al.
Publicado: (2019) -
Metabolite Dysregulation by Pranlukast in Mycobacterium tuberculosis
por: Yelamanchi, Soujanya D., et al.
Publicado: (2022) -
Rifampicin-Mediated Metabolic Changes in Mycobacterium tuberculosis
por: Yelamanchi, Soujanya D., et al.
Publicado: (2022)